Published in Br J Pharmacol on April 01, 2006
International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev (2008) 4.49
The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol (2013) 1.88
Signal transduction and information processing in mammalian taste buds. Pflugers Arch (2007) 1.80
Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol (2007) 1.64
In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience (2008) 1.36
Taking the time to study competitive antagonism. Br J Pharmacol (2007) 1.33
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.24
Coupling of energy metabolism and synaptic transmission at the transcriptional level: role of nuclear respiratory factor 1 in regulating both cytochrome c oxidase and NMDA glutamate receptor subunit genes. J Neurosci (2009) 1.23
Energy metabolism of the visual system. Eye Brain (2010) 1.18
Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol (2011) 1.17
Characterizing single-channel behavior of GluA3 receptors. Biophys J (2010) 1.09
Single-channel analysis of a point mutation of a conserved serine residue in the S2 ligand-binding domain of the NR2A NMDA receptor subunit. J Physiol (2006) 1.09
Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology (2013) 1.07
Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.07
Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci (2009) 1.04
TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology (2012) 0.96
SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study. Nanomedicine (2008) 0.93
Agonist-specific gating of NMDA receptors. Channels (Austin) (2010) 0.91
Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. Br J Pharmacol (2012) 0.89
How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia. Antioxid Redox Signal (2012) 0.82
Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies. Mol Brain (2008) 0.82
Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists. J Med Chem (2013) 0.81
Conformational transitions in the glycine-bound GluN1 NMDA receptor LBD via single-molecule FRET. Biophys J (2015) 0.80
2B or 2B and 2D? - that is the question. J Physiol (2008) 0.80
Pharmacological characterization of recombinant NR1/NR2A NMDA receptors with truncated and deleted carboxy termini expressed in Xenopus laevis oocytes. Br J Pharmacol (2009) 0.80
The conserved Candida albicans CA3427 gene product defines a new family of proteins exhibiting the generic periplasmic binding protein structural fold. PLoS One (2011) 0.76
Discovery of a new class of ionotropic glutamate receptor antagonists by the rational design of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid. ACS Chem Neurosci (2010) 0.76
The impact of commercially available purinergic ligands on purinergic signalling research. Purinergic Signal (2011) 0.75
Neuroprotective Mechanisms of Lycium barbarum Polysaccharides Against Ischemic Insults by Regulating NR2B and NR2A Containing NMDA Receptor Signaling Pathways. Front Cell Neurosci (2017) 0.75
Computational Investigation into the Interactions of Traditional Chinese Medicine Molecules of WenQingYin with GluR2. Int J Mol Sci (2017) 0.75
Vagotomy upregulates expression of the N-methyl-D-aspartate receptor NR2D subunit in the stomach. J Gastroenterol (2008) 0.75
The glutamate receptor ion channels. Pharmacol Rev (1999) 15.06
PDZ domain proteins of synapses. Nat Rev Neurosci (2004) 8.14
Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science (1992) 6.49
Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron (2000) 6.22
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol (1998) 5.93
Mechanism of glutamate receptor desensitization. Nature (2002) 5.36
Subunit arrangement and function in NMDA receptors. Nature (2005) 5.21
Receptor trafficking and synaptic plasticity. Nat Rev Neurosci (2004) 5.12
Structural basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci (2003) 4.55
Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci (2002) 4.30
Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature (1998) 4.14
Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J (2003) 3.15
The Yin and Yang of NMDA receptor signalling. Trends Neurosci (2003) 2.83
The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron (1993) 2.67
Crystal structures of the GluR5 and GluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity. Neuron (2005) 2.65
Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron (1997) 2.54
Trafficking of NMDA receptors. Annu Rev Pharmacol Toxicol (2002) 2.45
Glutamate receptor gating. Crit Rev Neurobiol (2004) 2.31
Structure and function of glutamate receptor ion channels. Annu Rev Physiol (2004) 2.29
Three-dimensional structures of the periplasmic lysine/arginine/ornithine-binding protein with and without a ligand. J Biol Chem (1993) 2.27
Structure and different conformational states of native AMPA receptor complexes. Nature (2005) 2.22
A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron (1998) 2.18
Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins. Neuron (1994) 2.15
Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci (2005) 2.11
Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron (1994) 2.11
A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron (1990) 2.10
Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron (2005) 2.07
Regulation of AMPA receptor gating by ligand binding core dimers. Neuron (2004) 2.06
Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci (2005) 1.97
The KA-2 subunit of excitatory amino acid receptors shows widespread expression in brain and forms ion channels with distantly related subunits. Neuron (1992) 1.97
Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes. Proc Natl Acad Sci U S A (2003) 1.81
Glutamate receptor ion channels. Curr Opin Neurobiol (2005) 1.79
Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors. J Neurosci (2001) 1.75
Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J Neurosci (2003) 1.73
AMPA receptor binding cleft mutations that alter affinity, efficacy, and recovery from desensitization. J Neurosci (2005) 1.70
Structure and function of AMPA receptors. J Physiol (2003) 1.64
Molecular dissection of the agonist binding site of an AMPA receptor. EMBO J (1995) 1.57
Structure and action of the nicotinic acetylcholine receptor explored by electron microscopy. FEBS Lett (2003) 1.56
Functional assembly of AMPA and kainate receptors is mediated by several discrete protein-protein interactions. Neuron (2001) 1.52
Structure of the kainate receptor subunit GluR6 agonist-binding domain complexed with domoic acid. Proc Natl Acad Sci U S A (2005) 1.48
The Venus flytrap of periplasmic binding proteins: an ancient protein module present in multiple drug receptors. AAPS PharmSci (1999) 1.47
The outer pore of the glutamate receptor channel has 2-fold rotational symmetry. Neuron (2004) 1.46
Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate. Biochemistry (2002) 1.45
Structural basis for AMPA receptor activation and ligand selectivity: crystal structures of five agonist complexes with the GluR2 ligand-binding core. J Mol Biol (2002) 1.44
Structure and gating of the glutamate receptor ion channel. Trends Neurosci (2004) 1.43
The Three-dimensional Structure of an Ionotropic Glutamate Receptor Reveals a Dimer-of-dimers Assembly. J Mol Biol (2004) 1.38
Block of AMPA receptor desensitization by a point mutation outside the ligand-binding domain. J Neurosci (2004) 1.33
Characterization of the ligand-binding domains of glutamate receptor (GluR)-B and GluR-D subunits expressed in Escherichia coli as periplasmic proteins. J Biol Chem (1996) 1.33
Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33
Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci (1998) 1.32
Glutamate receptor trafficking: endoplasmic reticulum quality control involves ligand binding and receptor function. J Neurosci (2005) 1.25
Crystal structure of the kainate receptor GluR5 ligand-binding core in complex with (S)-glutamate. FEBS Lett (2005) 1.22
The bacterial periplasmic histidine-binding protein. structure/function analysis of the ligand-binding site and comparison with related proteins. J Biol Chem (1994) 1.21
Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20
Identification of amino acid residues that control functional behavior in GluR5 and GluR6 kainate receptors. Neuron (1997) 1.18
Functional stoichiometry of glutamate receptor desensitization. J Neurosci (2002) 1.15
Function and structure in glycine receptors and some of their relatives. Trends Neurosci (2004) 1.14
Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit. Mol Pharmacol (1996) 1.12
Subunit interactions and AMPA receptor desensitization. J Neurosci (2001) 1.10
Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J Med Chem (2003) 1.10
Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket. J Pharmacol Exp Ther (2005) 1.03
Ligand binding is a critical requirement for plasma membrane expression of heteromeric kainate receptors. J Biol Chem (2004) 1.03
Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptor. Neuropharmacology (2004) 1.03
Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol Pharmacol (1998) 1.03
Structural determinants of agonist-specific kinetics at the ionotropic glutamate receptor 2. Proc Natl Acad Sci U S A (2005) 1.02
Tweaking agonist efficacy at N-methyl-D-aspartate receptors by site-directed mutagenesis. Mol Pharmacol (2005) 0.98
First images of a glutamate receptor ion channel: oligomeric state and molecular dimensions of GluRB homomers. Biochemistry (2001) 0.96
Amino terminal domain regulation of NMDA receptor function. Eur J Pharmacol (2004) 0.96
Binding site flexibility: molecular simulation of partial and full agonists within a glutamate receptor. Mol Pharmacol (2005) 0.96
Three-dimensional structure of the ligand-binding core of GluR2 in complex with the agonist (S)-ATPA: implications for receptor subunit selectivity. J Med Chem (2003) 0.95
Ligand-binding residues integrate affinity and efficacy in the NMDA receptor. Mol Pharmacol (2004) 0.94
Single-channel analysis of an NMDA receptor possessing a mutation in the region of the glutamate binding site. J Physiol (2000) 0.92
A binding site tyrosine shapes desensitization kinetics and agonist potency at GluR2. A mutagenic, kinetic, and crystallographic study. J Biol Chem (2005) 0.92
Selective agonist binding of (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) and 2S-(2alpha,3beta,4beta)-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid (kainate) receptors: a molecular modeling study. Biochem Pharmacol (2003) 0.92
Mutations in the ligand-binding and pore domains control exit of glutamate receptors from the endoplasmic reticulum in C. elegans. Neuropharmacology (2003) 0.89
Tyr702 is an important determinant of agonist binding and domain closure of the ligand-binding core of GluR2. Mol Pharmacol (2004) 0.89
Arginine-481 mutation abolishes ligand-binding of the AMPA-selective glutamate receptor channel alpha1-subunit. Brain Res Mol Brain Res (1997) 0.86
Identification of amino acid residues in GluR1 responsible for ligand binding and desensitization. J Neurosci (2001) 0.86
Influence of a threonine residue in the S2 ligand binding domain in determining agonist potency and deactivation rate of recombinant NR1a/NR2D NMDA receptors. J Physiol (2004) 0.85
Structural basis for understanding structure-activity relationships for the glutamate binding site of the NMDA receptor. J Med Chem (2002) 0.83
Evolutionary trace analysis of ionotropic glutamate receptor sequences and modeling the interactions of agonists with different NMDA receptor subunits. J Mol Model (2004) 0.80
The selective activation of the glutamate receptor GluR5 by ATPA is controlled by serine 741. Mol Pharmacol (2003) 0.80
A molecular envelope of the ligand-binding domain of a glutamate receptor in the presence and absence of agonist. Biochemistry (1999) 0.79
Comparative analysis of different competitive antagonists interaction with NR2A and NR2B subunits of N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor. J Mol Model (2005) 0.78
The importance of two specific domains in ligand binding to the AMPA/kainate glutamate receptors GluR2 and GluR6. FEBS Lett (1995) 0.77
Development of a three-dimensional model for the N-methyl-D-aspartate NR2A subunit. J Med Chem (2005) 0.76
Discrimination between agonists and antagonists by the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-selective glutamate receptor. A mutation analysis of the ligand-binding domain of GluR-D subunit. J Biol Chem (2002) 0.76
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci (2008) 4.04
Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol (2005) 2.90
Glutamate receptor gating. Crit Rev Neurobiol (2004) 2.31
Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A (2012) 2.14
The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron (2012) 1.97
Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci (2008) 1.58
Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol (2007) 1.56
Homeostasis of intrinsic excitability in hippocampal neurones: dynamics and mechanism of the response to chronic depolarization. J Physiol (2009) 1.41
Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci (2010) 1.39
Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33
Mitochondrial calcium uniporter Mcu controls excitotoxicity and is transcriptionally repressed by neuroprotective nuclear calcium signals. Nat Commun (2013) 1.30
Activin/Nodal inhibition alone accelerates highly efficient neural conversion from human embryonic stem cells and imposes a caudal positional identity. PLoS One (2009) 1.24
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.24
Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Sci Transl Med (2013) 1.11
Induction and maintenance of late-phase long-term potentiation in isolated dendrites of rat hippocampal CA1 pyramidal neurones. J Physiol (2005) 1.07
Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.07
Phosphatidylinositol 3 kinase activation and AMPA receptor subunit trafficking underlie the potentiation of miniature EPSC amplitudes triggered by the activation of L-type calcium channels. J Neurosci (2006) 1.01
Neuronal homeostasis: time for a change? J Physiol (2011) 0.99
Fragile X syndrome: from targets to treatments. Neuropharmacology (2012) 0.95
Maturation of AMPAR composition and the GABAAR reversal potential in hPSC-derived cortical neurons. J Neurosci (2014) 0.94
PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity. J Neurosci (2012) 0.87
Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression. Channels (Austin) (2009) 0.86
Influence of a threonine residue in the S2 ligand binding domain in determining agonist potency and deactivation rate of recombinant NR1a/NR2D NMDA receptors. J Physiol (2004) 0.85
Generation of functional neurons from feeder-free, keratinocyte-derived equine induced pluripotent stem cells. Stem Cells Dev (2014) 0.85
VCP binding influences intracellular distribution of the slow Wallerian degeneration protein, Wld(S). Mol Cell Neurosci (2008) 0.83
Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis. J Neurochem (2012) 0.83
Single-channel properties of N-methyl-D-aspartate receptors containing chimaeric GluN2A/GluN2D subunits. Biochem Soc Trans (2009) 0.80
3-Fluoro-N-methyl-D-aspartic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors. Chemistry (2012) 0.79
Inhibition of rat recombinant GluN1/GluN2A and GluN1/GluN2B NMDA receptors by ethanol at concentrations based on the US/UK drink-drive limit. Eur J Pharmacol (2009) 0.79
Recovery of NMDA receptor currents from MK-801 blockade is accelerated by Mg2+ and memantine under conditions of agonist exposure. Neuropharmacology (2013) 0.76
The ups and downs of synaptic plasticity: influences on this particular 'market'. J Physiol (2008) 0.75
Inhibition of recombinant GluN1/GluN2A and GluN1/GluN2B N-methyl-D-aspartate receptors by single malt whiskies. Biochem Soc Trans (2009) 0.75